Remdesivir

Remdesivir is a revolutionary nucleotide analogue prodrug that has transformed the treatment landscape for severe viral infections, most notably COVID-19. As a broad-spectrum antiviral agent, Remdesivir has demonstrated activity against multiple RNA virus families including coronaviruses (SARS-CoV, MERS-CoV, SARS-CoV-2), filoviruses (Ebola, Marburg), and paramyxoviruses. Remdesivir is administered intravenously and is converted intracellularly to the active triphosphate metabolite, which inhibits viral RNA-dependent RNA polymerase and terminates viral RNA chain elongation. The FDA granted full approval to Remdesivir for the treatment of COVID-19 in patients requiring hospitalization, making it a cornerstone of antiviral therapy during the pandemic. Remdesivir continues to be studied for other viral infections and as a potential therapeutic for emerging viral threats. The compound is supplied as a high-purity research grade material (≥98% HPLC) for antiviral research, formulation development, and analytical reference applications.

 

Product Parameters

---

Parameter	Specification
Product Name	Remdesivir
CAS Number	1809249-37-3
Molecular Formula	C₂₇H₃₅N₆O₈P
Molecular Weight	602.58 g/mol
Appearance	White solid
Density	1.47±0.1 g/cm3
pKa	12.00±0.70
Storage Condition	Store at -20°C

 

Application

---

Product Advantages: Remdesivir is a nucleoside analog under development by Gilead Sciences. On May 7, 2020, the Japanese government approved the drug remdesivir developed by Gilead Sciences (GILD.US) for the treatment of COVID-19, making it the first officially approved medication for COVID-19-related diseases in Japan, with priority use for severe cases. Remdesivir has not yet received approval or authorization outside Japan; however, in May 2020, it was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA). Although not yet formally approved for market release by the FDA, its market potential is significant, and it holds considerable strategic value as a therapeutic agent. Remdesivir exhibits broad-spectrum antiviral activity, demonstrating efficacy against various emerging viral pathogens in both in vitro and animal model studies, including Ebola virus, Marburg virus, Middle East Respiratory Syndrome (MERS), and SARS-CoV-2. Therefore, remdesivir is likely to play a therapeutic role in future outbreaks caused by similar viruses. To date, remdesivir has been approved for use in 41 countries and regions, including the United States, Japan, the United Kingdom, the European Union, the United Arab Emirates, India, and Canada, in various forms.

 

Antiviral drugs

---

Remdesivir belongs to the class of nucleoside analogs and acts as an inhibitor of RNA-dependent RNA polymerase (RdRp), exerting antiviral effects by suppressing viral nucleic acid synthesis. Current clinical trials targeting Ebola virus infection have progressed to Phase II. Mice infected with MERS virus exhibited significantly improved outcomes following treatment with this combination therapy, characterized by reduced viral replication and enhanced pulmonary function.

 

Yuen Kwok-Yung, a microbiologist at the University of Hong Kong, also considers remdesivir the most promising drug against 2019-nCoV and MERS. However, this drug has not yet been approved for use in China.

 

Two top-tier scientific journals have jointly stated that remdesivir, developed to combat the Ebola virus, may inadvertently become a potential solution for combating 2019-nCoV. On January 31, Chemicalbook published a statement by Dr. Merdad Parsey, the company's Chief Medical Officer, outlining the drug development efforts underway against the novel coronavirus (2019-nCoV).

 

Dr. Merdad Parsey stated in the announcement: "In response to the global outbreak of the 2019 novel coronavirus as a public health event, Gilead is currently engaging in close communication and collaboration with global healthcare regulatory authorities to advance clinical trials for our antiviral drug remdesivir. Gilead is committed to working together with the U.S. Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (DHHS), China's CDC, the World Health Organization (WHO), the National Institute of Allergy and Infectious Diseases (NIAID), as well as individual researchers and clinicians, to leverage our extensive experience and resources in antiviral drug development to support patients and institutions worldwide in combating 2019-nCoV."

 

Remdesivir has not yet been approved in any country or region worldwide, and its safety or efficacy for clinical use remains unproven. However, in response to clinicians' needs and to support the work of certain regulatory authorities, we have carefully evaluated the risks and benefits of this investigational drug, for which no data have been obtained regarding 2019-nCoV. Gilead has provided Remdesivir to a small number of patients requiring emergency treatment but lacking available therapeutic options.

 

Gilead is currently working closely with China's health authorities to initiate a randomized, controlled clinical trial as soon as possible to determine whether Remdesivir can be effectively used for the treatment of 2019-nCoV infection. We are also accelerating laboratory tests to evaluate the antiviral activity of remdesivir against 2019-nCoV.

 

Although no data currently demonstrate the anti-2019-nCoV activity of remdesivir, its demonstrated efficacy against other coronaviruses provides us with confidence. Remdesivir has shown significant antiviral activity against MERS and SARS viruses in vitro and animal models, which share structural similarities with 2019-nCoV. Additionally, we have available clinical data on the use of remdesivir for emergency treatment of Ebola virus infection patients.

 

Bioactivity

---

Remdesivir (GS-5734) is a nucleoside analog with antiviral activity, exhibiting an EC50 value of 74 nM against SARS-CoV and MERS-CoV in HAE cells, and an EC50 value of 30 nM against murine hepatitis virus in delayed brain tumor cells.

 

Contact Us

---

Your antiviral research or analytical program deserves a partner who understands the critical importance of compound quality and documentation. Cosperpharm delivers high-purity Remdesivir with the analytical rigor and responsive service that researchers and manufacturers need. Contact our team today to discuss your requirements, request a quote, or ask about our documentation packages.